Buyside

View more issues:

Articles in April, 2003 issue of Buyside

• Atrix Laboratories (Nasdaq: ATRX) Q4 in line; four-month Eligard launched. (Leerink Swann & Company).(financial analysis and rating)
  by Hearle, Michael J.; Tune, K. Noelle
• Endo Pharmaceuticals Inc.: NASDAQ: ENDP--$10.07: rating: buy. (Jefferies).
  by Rastogi, Hiranshu; Windley, David H.
• Pall Corporation (NYSE: PLL): Pall's profit push ahead.
• Something special: special situations investors look for stories that move stock prices.(Brief Article)
  by Dixon, Robert F.
• Waddell & Reed Financial. (Buyside on the Buy Side).(Brief Article)
• Maverick Tube Corporation: NYSE: MVK--$17.40: rating: buy. (Jefferies).
  by Fyhr, Magnus
• Weatherford[R]: [NYSE Symbol: WFT]: product & service leadership global market reach step change technologies.(Brief Article)
• RBC Funds changed the management team of the Royal Precious Metals Fund. (Buyside on the Buy Side).(Brief Article)
• Global view. (Analyst Profile).
  by Leerskov, Meghan
• Southern Company: NYSE: SO: rating: buy. (Jefferies).
  by Fremont. Paul
• StarMine's sector champions. (Guiding Lights).
• Minefinders Corporation Ltd.(financial analysis)
• Data delivery: Ford Equity Research team relies on the fundamentals. (Sell-Side Focus).
  by Serva, Sandy
• Questar: Questar's value proposition is simple: natural gas demand in the U.S. is set to grow by 30% over the next decade, and we are prepared to exploit this growth. Our integrated, Rockies-focused assets place us at the "hub of western energy devel
• Regis Corporation (RGIS $27.04) buy. (Research Update).
  by Krueger, Christopher W.
• How Swede it is. (Analyst Showcase).
  by Chensvold, Christian M.
• Getting in on the ground floor. (Special report: service sector stocks).
  by Haines, Leslie
• OMI Corporation; company Rating: buy (Fulcrum Global Partners).
• CI Mutual Funds. (Buyside on the Buy Side).(Brief Article)
• BP.(strategies)
  by Browne, John
• Citibank depositary receipt issuers.(Illustration)
• Schnitzer Steel Industries, Inc.: SCHN *--OTC--$26.55. (Institutional Equity Research).
  by Rogers, John
• Healthy research: Leerink Swann prospers by focusing on medical niche. (Research Profile).
  by Serva, Sandy
• Strong momentum: while other firms flounder, Jefferies builds a powerful research team. (Research Profile).
  by Leerskov, Meghan
• Coming clean: filtration companies outperform broader industrial sectors.
  by Dixon, Robert F.
• Profitable curiosity. (Money Manager).
  by Serva, Sandy
• Goizueta Directors Institute hosts conference on corporate governance. (Cultural Reality Check).(Brief Article)
• Thomson's new product helps investor relations professionals comply with Sarbanes-Oxley Act. (Clear Vision).(Brief Article)
• Frontline Ltd.: NYSE: FRO--$11.45: rating: buy. (Jefferies).
  by Fyhr, Magnus
• Service buys: the oilfield-service sector offers some hidden investment opportunities. (Special report: service sector stocks).(Industry Overview)
  by Snow, Nick
• Rita Medical Systems Inc.: (RITA: NasdaqNM)--$4.65. (Equity Research).(financial analysis)
  by Smillie, Mark F.
• Franklin Templeton Investments. (Buyside on the Buy Side).(Brief Article)
• Dominion Resources, Inc.: NYSE: D--$54.05 rating: buy. (Jefferies).
  by Fremont, Paul
• Black Hills Corporation: BKH--NYSE--$23.70. (Institutional Equity Research).
  by Bellessa, James L., Jr.
• Good growers: Stocks that bloomed in 2002.
• From deflation to re-inflation: how to protect your portfolio. (Guest Column).
  by Midanek, Jim; Pak, John
• Small stands tall! (Publisher's Letter).
  by Patrick, Jim
• Regulation wins. (Analyst Showcase).
  by Chensvold, Christian M.
• Portland's trailblazers: D.A. Davidson utilizes its regional knowledge to go beyond the street. (Research Profile).
  by Leerskov, Meghan
• BioCryst Pharmaceuticals, Inc.: corporate fact sheet: April 2003.(Company Profile)
• Designed for success: medical device sector expected to soar.
  by McReynolds, Rebecca
• Verizon Communications Inc. NYSE: VZ. (verizon).(strategy and stock analysis)
• Beyond the silo: MJSK team discovers flourishing companies within small-cap arena. (Research Profile).
  by Serva, Sandy
• Scientific Games Corporation: NASDAQ: SGMS--$4.85: rating: buy. (Jefferies).
  by Baron, David R.; Klatzkin, Lawrence A.; Marcel, Aimee K.; Rickert, Maria L.
• An uncertain brew: threat of war adds a new and worrying element to volatile energy markets.
  by O'Connor, Robert
• iDine Rewards Network; company rating: buy. (Fulcrum Global Partners).
• Scotia Securities. (Buyside on the Buy Side).(Brief Article)
• Teekay Shipping Corporation: NYSE: TK--$36.45: rating: buy. (Jefferies).
  by Fyhr, Magnus
• Conference calendar.(Calendar)
• Taking stock: increasing the accuracy of new drug revenue forecasts.
  by Bennett, Brian; Eng, Steve
• New report forecasts public companies filing chapter 11 to reach $240 billion in 2003. (Going Bust).(Brief Article)
• Orthofix[R]. (Corporate Sponsored Profile).(Company Profile)